AGILENT TECHNOLOGIES, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that AGILENT TECHNOLOGIES, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Oct 31, 2017 | $4.47B | Dec 21, 2017 |
| FY2017 | Oct 31, 2016 | $4.20B | Dec 21, 2017 |
| FY2017 | Oct 31, 2015 | $4.04B | Dec 21, 2017 |
| FY2016 | Oct 31, 2014 | $4.05B | Dec 20, 2016 |
| FY2015 | Oct 31, 2013 | $3.89B | Dec 21, 2015 |
| FY2012 | Oct 31, 2012 | $6.86B | Dec 20, 2012 |
| FY2012 | Oct 31, 2011 | $6.62B | Dec 20, 2012 |
| FY2012 | Oct 31, 2010 | $5.44B | Dec 20, 2012 |
| FY2011 | Oct 31, 2009 | $4.48B | Dec 16, 2011 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $6.95B | Dec 22, 2025 |
| FY2025 | Oct 31, 2024 | $6.51B | Dec 22, 2025 |
| FY2025 | Oct 31, 2023 | $6.83B | Dec 22, 2025 |
| FY2024 | Oct 31, 2022 | $6.85B | Dec 20, 2024 |
| FY2023 | Oct 31, 2021 | $6.32B | Dec 20, 2023 |
| FY2022 | Oct 31, 2020 | $5.34B | Dec 21, 2022 |
| FY2021 | Oct 31, 2019 | $5.16B | Dec 17, 2021 |
| FY2020 | Oct 31, 2018 | $4.91B | Dec 18, 2020 |
| FY2019 | Oct 31, 2017 | $4.47B | Dec 19, 2019 |
| FY2018 | Oct 31, 2016 | $4.20B | Dec 20, 2018 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Oct 31, 2017 | $4.47B | Dec 21, 2017 |
| FY2017 | Oct 31, 2016 | $4.20B | Dec 21, 2017 |
| FY2017 | Oct 31, 2015 | $4.04B | Dec 21, 2017 |
| FY2016 | Oct 31, 2014 | $4.05B | Dec 20, 2016 |
| FY2015 | Oct 31, 2013 | $3.89B | Dec 21, 2015 |
| FY2014 | Oct 31, 2012 | $6.86B | Dec 22, 2014 |
| FY2013 | Oct 31, 2011 | $6.62B | Dec 19, 2013 |
| FY2012 | Oct 31, 2010 | $5.44B | Dec 20, 2012 |
| FY2011 | Oct 31, 2009 | $4.48B | Dec 16, 2011 |
| FY2010 | Oct 31, 2008 | $5.77B | Dec 20, 2010 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $1.30B | Dec 22, 2025 |
| FY2025 | Oct 31, 2024 | $1.29B | Dec 22, 2025 |
| FY2025 | Oct 31, 2023 | $1.24B | Dec 22, 2025 |
| FY2024 | Oct 31, 2022 | $1.25B | Dec 20, 2024 |
| FY2023 | Oct 31, 2021 | $1.21B | Dec 20, 2023 |
| FY2022 | Oct 31, 2020 | $719.00M | Dec 21, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $1.48B | Dec 22, 2025 |
| FY2025 | Oct 31, 2024 | $1.49B | Dec 22, 2025 |
| FY2025 | Oct 31, 2023 | $1.35B | Dec 22, 2025 |
| FY2024 | Oct 31, 2022 | $1.62B | Dec 20, 2024 |
| FY2023 | Oct 31, 2021 | $1.35B | Dec 20, 2023 |
| FY2022 | Oct 31, 2020 | $846.00M | Dec 21, 2022 |
| FY2021 | Oct 31, 2019 | $941.00M | Dec 17, 2021 |
| FY2020 | Oct 31, 2018 | $904.00M | Dec 18, 2020 |
| FY2019 | Oct 31, 2017 | $807.00M | Dec 19, 2019 |
| FY2018 | Oct 31, 2016 | $615.00M | Dec 20, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $455.00M | Dec 22, 2025 |
| FY2025 | Oct 31, 2024 | $479.00M | Dec 22, 2025 |
| FY2025 | Oct 31, 2023 | $481.00M | Dec 22, 2025 |
| FY2024 | Oct 31, 2022 | $467.00M | Dec 20, 2024 |
| FY2023 | Oct 31, 2021 | $441.00M | Dec 20, 2023 |
| FY2022 | Oct 31, 2020 | $495.00M | Dec 21, 2022 |
| FY2021 | Oct 31, 2019 | $404.00M | Dec 17, 2021 |
| FY2020 | Oct 31, 2018 | $387.00M | Dec 18, 2020 |
| FY2019 | Oct 31, 2017 | $341.00M | Dec 19, 2019 |
| FY2018 | Oct 31, 2016 | $329.00M | Dec 20, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $1.71B | Dec 22, 2025 |
| FY2025 | Oct 31, 2024 | $1.57B | Dec 22, 2025 |
| FY2025 | Oct 31, 2023 | $1.63B | Dec 22, 2025 |
| FY2024 | Oct 31, 2022 | $1.64B | Dec 20, 2024 |
| FY2023 | Oct 31, 2021 | $1.62B | Dec 20, 2023 |
| FY2022 | Oct 31, 2020 | $1.50B | Dec 21, 2022 |
| FY2021 | Oct 31, 2019 | $1.46B | Dec 17, 2021 |
| FY2020 | Oct 31, 2018 | $1.39B | Dec 18, 2020 |
| FY2019 | Oct 31, 2017 | $1.25B | Dec 19, 2019 |
| FY2018 | Oct 31, 2016 | $1.25B | Dec 20, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $1.56B | Dec 22, 2025 |
| FY2025 | Oct 31, 2024 | $1.75B | Dec 22, 2025 |
| FY2025 | Oct 31, 2023 | $1.77B | Dec 22, 2025 |
| FY2024 | Oct 31, 2022 | $1.31B | Dec 20, 2024 |
| FY2023 | Oct 31, 2021 | $1.49B | Dec 20, 2023 |
| FY2022 | Oct 31, 2020 | $921.00M | Dec 21, 2022 |
| FY2021 | Oct 31, 2019 | $1.02B | Dec 17, 2021 |
| FY2020 | Oct 31, 2018 | $1.09B | Dec 18, 2020 |
| FY2019 | Oct 31, 2017 | $889.00M | Dec 19, 2019 |
| FY2018 | Oct 31, 2016 | $793.00M | Dec 20, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $407.00M | Dec 22, 2025 |
| FY2025 | Oct 31, 2024 | $378.00M | Dec 22, 2025 |
| FY2025 | Oct 31, 2023 | $298.00M | Dec 22, 2025 |
| FY2024 | Oct 31, 2022 | $291.00M | Dec 20, 2024 |
| FY2023 | Oct 31, 2021 | $188.00M | Dec 20, 2023 |
| FY2022 | Oct 31, 2020 | $119.00M | Dec 21, 2022 |
| FY2021 | Oct 31, 2019 | $155.00M | Dec 17, 2021 |
| FY2020 | Oct 31, 2018 | $177.00M | Dec 18, 2020 |
| FY2019 | Oct 31, 2017 | $176.00M | Dec 19, 2019 |
| FY2018 | Oct 31, 2016 | $139.00M | Dec 20, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $12.73B | Dec 22, 2025 |
| FY2025 | Oct 31, 2024 | $11.85B | Dec 22, 2025 |
| FY2024 | Oct 31, 2023 | $10.76B | Dec 20, 2024 |
| FY2023 | Oct 31, 2022 | $10.53B | Dec 20, 2023 |
| FY2022 | Oct 31, 2021 | $10.71B | Dec 21, 2022 |
| FY2021 | Oct 31, 2020 | $9.63B | Dec 17, 2021 |
| FY2020 | Oct 31, 2019 | $9.45B | Dec 18, 2020 |
| FY2019 | Nov 1, 2018 | $8.56B | Dec 19, 2019 |
| FY2019 | Oct 31, 2018 | $8.54B | Dec 19, 2019 |
| FY2018 | Oct 31, 2017 | $8.43B | Dec 20, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $5.99B | Dec 22, 2025 |
| FY2025 | Oct 31, 2024 | $5.95B | Dec 22, 2025 |
| FY2024 | Oct 31, 2023 | $4.92B | Dec 20, 2024 |
| FY2023 | Oct 31, 2022 | $5.23B | Dec 20, 2023 |
| FY2022 | Oct 31, 2021 | $5.32B | Dec 21, 2022 |
| FY2021 | Oct 31, 2020 | $4.75B | Dec 17, 2021 |
| FY2020 | Oct 31, 2019 | $4.70B | Dec 18, 2020 |
| FY2019 | Nov 1, 2018 | $3.96B | Dec 19, 2019 |
| FY2019 | Oct 31, 2018 | $3.97B | Dec 19, 2019 |
| FY2018 | Oct 31, 2017 | $3.59B | Dec 20, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $6.74B | Dec 22, 2025 |
| FY2025 | Oct 31, 2024 | $5.90B | Dec 22, 2025 |
| FY2024 | Oct 31, 2023 | $5.85B | Dec 20, 2024 |
| FY2023 | Oct 31, 2022 | $5.31B | Dec 20, 2023 |
| FY2022 | Oct 31, 2021 | $5.39B | Dec 21, 2022 |
| FY2021 | Oct 31, 2020 | $4.87B | Dec 17, 2021 |
| FY2020 | Oct 31, 2019 | $4.75B | Dec 18, 2020 |
| FY2019 | Nov 1, 2018 | $4.59B | Dec 19, 2019 |
| FY2019 | Oct 31, 2018 | $4.57B | Dec 19, 2019 |
| FY2018 | Oct 31, 2017 | $4.83B | Dec 20, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $4.47B | Dec 22, 2025 |
| FY2025 | Oct 31, 2024 | $4.48B | Dec 22, 2025 |
| FY2025 | Oct 31, 2023 | $3.96B | Dec 22, 2025 |
| FY2024 | Oct 31, 2022 | $3.95B | Dec 20, 2024 |
| FY2023 | Oct 31, 2021 | $3.98B | Dec 20, 2023 |
| FY2022 | Oct 31, 2020 | $3.60B | Dec 21, 2022 |
| FY2021 | Oct 31, 2019 | $3.59B | Dec 17, 2021 |
| FY2019 | Nov 1, 2018 | $2.97B | Dec 19, 2019 |
| FY2020 | Oct 31, 2018 | $2.97B | Dec 18, 2020 |
| FY2019 | Oct 31, 2017 | $2.61B | Dec 19, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $1.39B | Dec 22, 2025 |
| FY2025 | Oct 31, 2024 | $750.00M | Dec 22, 2025 |
| FY2024 | Oct 31, 2023 | $782.00M | Dec 20, 2024 |
| FY2023 | Oct 31, 2022 | $324.00M | Dec 20, 2023 |
| FY2022 | Oct 31, 2021 | $348.00M | Dec 21, 2022 |
| FY2021 | Oct 31, 2020 | $81.00M | Dec 17, 2021 |
| FY2020 | Oct 31, 2019 | ($18.00M) | Dec 18, 2020 |
| FY2019 | Nov 1, 2018 | ($303.00M) | Dec 19, 2019 |
| FY2019 | Oct 31, 2018 | ($336.00M) | Dec 19, 2019 |
| FY2018 | Oct 31, 2017 | ($126.00M) | Dec 20, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $1.79B | Dec 22, 2025 |
| FY2025 | Oct 31, 2024 | $1.33B | Dec 22, 2025 |
| FY2025 | Oct 31, 2023 | $1.59B | Dec 22, 2025 |
| FY2024 | Oct 31, 2022 | $1.05B | Dec 20, 2024 |
| FY2023 | Oct 31, 2021 | $1.48B | Dec 20, 2023 |
| FY2022 | Oct 31, 2020 | $1.44B | Dec 21, 2022 |
| FY2021 | Oct 31, 2019 | $1.38B | Dec 17, 2021 |
| FY2019 | Nov 1, 2018 | $2.25B | Dec 19, 2019 |
| FY2020 | Oct 31, 2018 | $2.25B | Dec 18, 2020 |
| FY2019 | Oct 31, 2017 | $2.68B | Dec 19, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $3.05B | Dec 22, 2025 |
| FY2025 | Oct 31, 2024 | $3.35B | Dec 22, 2025 |
| FY2024 | Oct 31, 2023 | $2.74B | Dec 20, 2024 |
| FY2023 | Oct 31, 2022 | $2.73B | Dec 20, 2023 |
| FY2022 | Oct 31, 2021 | $2.73B | Dec 21, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | 4 | Dec 22, 2025 |
| FY2025 | Oct 31, 2024 | 4 | Dec 22, 2025 |
| FY2025 | Oct 31, 2023 | 4 | Dec 22, 2025 |
| FY2024 | Oct 31, 2022 | 4 | Dec 20, 2024 |
| FY2023 | Oct 31, 2021 | 3 | Dec 20, 2023 |
| FY2022 | Oct 31, 2020 | 2 | Dec 21, 2022 |
| FY2021 | Oct 31, 2019 | 3 | Dec 17, 2021 |
| FY2020 | Oct 31, 2018 | 0 | Dec 18, 2020 |
| FY2019 | Oct 31, 2017 | 2 | Dec 19, 2019 |
| FY2018 | Oct 31, 2016 | 1 | Dec 20, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | 4 | Dec 22, 2025 |
| FY2025 | Oct 31, 2024 | 4 | Dec 22, 2025 |
| FY2025 | Oct 31, 2023 | 4 | Dec 22, 2025 |
| FY2024 | Oct 31, 2022 | 4 | Dec 20, 2024 |
| FY2023 | Oct 31, 2021 | 3 | Dec 20, 2023 |
| FY2022 | Oct 31, 2020 | 2 | Dec 21, 2022 |
| FY2021 | Oct 31, 2019 | 3 | Dec 17, 2021 |
| FY2020 | Oct 31, 2018 | 0 | Dec 18, 2020 |
| FY2019 | Oct 31, 2017 | 2 | Dec 19, 2019 |
| FY2018 | Oct 31, 2016 | 1 | Dec 20, 2018 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | 283.05M | Dec 22, 2025 |
| FY2025 | Oct 31, 2024 | 285.19M | Dec 22, 2025 |
| FY2024 | Oct 31, 2023 | 292.12M | Dec 20, 2024 |
| FY2023 | Oct 31, 2022 | 295.26M | Dec 20, 2023 |
| FY2022 | Oct 31, 2021 | 302.00M | Dec 21, 2022 |
| FY2021 | Oct 31, 2020 | 306.00M | Dec 17, 2021 |
| FY2020 | Oct 31, 2019 | 309.00M | Dec 18, 2020 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $282.00M | Dec 22, 2025 |
| FY2025 | Oct 31, 2024 | $274.00M | Dec 22, 2025 |
| FY2025 | Oct 31, 2023 | $265.00M | Dec 22, 2025 |
| FY2024 | Oct 31, 2022 | $250.00M | Dec 20, 2024 |
| FY2023 | Oct 31, 2021 | $236.00M | Dec 20, 2023 |
| FY2022 | Oct 31, 2020 | $222.00M | Dec 21, 2022 |
| FY2021 | Oct 31, 2019 | $206.00M | Dec 17, 2021 |
| FY2020 | Oct 31, 2018 | $191.00M | Dec 18, 2020 |
| FY2019 | Oct 31, 2017 | $170.00M | Dec 19, 2019 |
| FY2018 | Oct 31, 2016 | $150.00M | Dec 20, 2018 |